<DOC>
	<DOCNO>NCT01944527</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety tolerability direct-acting antiviral therapy liver transplant patient experience HCV recurrence . This cohort multicentric constitution biobank ( plasma , serum ) prospective collect biological clinical data 's liver transplant patient recurrent HCV infection treat direct-acting anti-HCV agent .</brief_summary>
	<brief_title>Use Direct-acting Antiviral Treat HCV Recurrence After Liver Transplantation ( ANRSCO23CUPILT ) Infection</brief_title>
	<detailed_description />
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Age &gt; 18 yearsold Liver transplant patient Hepatitis C virus infection transplantation HCV recurrence detectable HCV RNA enrollment cohort Use least one directacting antiviral agent without association peginterferon without association ribavirin Treated directacting antiviral agent yet complete treatment still follow Affiliated Health Insurance Written Signed consent form Pregnant breastfeeding female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>